225 related articles for article (PubMed ID: 31904482)
1. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers.
Wang Y; Lu JH; Wang F; Wang YN; He MM; Wu QN; Lu YX; Yu HE; Chen ZH; Zhao Q; Liu J; Chen YX; Wang DS; Sheng H; Liu ZX; Zeng ZL; Xu RH; Ju HQ
Cancer Lett; 2020 Mar; 473():74-89. PubMed ID: 31904482
[TBL] [Abstract][Full Text] [Related]
2. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
3. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4
Brown ZJ; Fu Q; Ma C; Kruhlak M; Zhang H; Luo J; Heinrich B; Yu SJ; Zhang Q; Wilson A; Shi ZD; Swenson R; Greten TF
Cell Death Dis; 2018 May; 9(6):620. PubMed ID: 29795111
[TBL] [Abstract][Full Text] [Related]
4. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation.
Wang YN; Lu YX; Liu J; Jin Y; Bi HC; Zhao Q; Liu ZX; Li YQ; Hu JJ; Sheng H; Jiang YM; Zhang C; Tian F; Chen Y; Pan ZZ; Chen G; Zeng ZL; Liu KY; Ogasawara M; Yun JP; Ju HQ; Feng JX; Xie D; Gao S; Jia WH; Kopetz S; Xu RH; Wang F
Oncogene; 2020 Jan; 39(3):637-650. PubMed ID: 31530934
[TBL] [Abstract][Full Text] [Related]
5. The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress.
Chen W; Lian W; Yuan Y; Li M
Cell Death Dis; 2019 Aug; 10(8):600. PubMed ID: 31395855
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Nukatsuka M; Nakagawa F; Takechi T
Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
[TBL] [Abstract][Full Text] [Related]
7. Ursolic acid enhances the therapeutic effects of oxaliplatin in colorectal cancer by inhibition of drug resistance.
Zhang Y; Huang L; Shi H; Chen H; Tao J; Shen R; Wang T
Cancer Sci; 2018 Jan; 109(1):94-102. PubMed ID: 29034540
[TBL] [Abstract][Full Text] [Related]
8. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexiline.
Liu PP; Liu J; Jiang WQ; Carew JS; Ogasawara MA; Pelicano H; Croce CM; Estrov Z; Xu RH; Keating MJ; Huang P
Oncogene; 2016 Oct; 35(43):5663-5673. PubMed ID: 27065330
[TBL] [Abstract][Full Text] [Related]
9. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
10. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
Sawada N; Kondoh K; Mori K
Oncol Rep; 2007 Oct; 18(4):775-8. PubMed ID: 17786335
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Ascorbate Suppresses Growth of Gastric Cancer Cells with GLUT1 Overexpression and Enhances the Efficacy of Oxaliplatin Through Redox Modulation.
Lu YX; Wu QN; Chen DL; Chen LZ; Wang ZX; Ren C; Mo HY; Chen Y; Sheng H; Wang YN; Wang Y; Lu JH; Wang DS; Zeng ZL; Wang F; Wang FH; Li YH; Ju HQ; Xu RH
Theranostics; 2018; 8(5):1312-1326. PubMed ID: 29507622
[No Abstract] [Full Text] [Related]
13. Baicalin enhances the chemotherapy sensitivity of oxaliplatin-resistant gastric cancer cells by activating p53-mediated ferroptosis.
Shao L; Zhu L; Su R; Yang C; Gao X; Xu Y; Wang H; Guo C; Li H
Sci Rep; 2024 May; 14(1):10745. PubMed ID: 38730240
[TBL] [Abstract][Full Text] [Related]
14. Ethaselen synergizes with oxaliplatin in tumor growth inhibition by inducing ROS production and inhibiting TrxR1 activity in gastric cancer.
Zhang H; Wu J; Yuan J; Li H; Zhang Y; Wu W; Chen W; Wang C; Meng S; Chen S; Huo M; He Y; Zhang C
J Exp Clin Cancer Res; 2021 Aug; 40(1):260. PubMed ID: 34412665
[TBL] [Abstract][Full Text] [Related]
15. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (
Combès E; Andrade AF; Tosi D; Michaud HA; Coquel F; Garambois V; Desigaud D; Jarlier M; Coquelle A; Pasero P; Bonnefoy N; Moreaux J; Martineau P; Del Rio M; Beijersbergen RL; Vezzio-Vie N; Gongora C
Cancer Res; 2019 Jun; 79(11):2933-2946. PubMed ID: 30987998
[TBL] [Abstract][Full Text] [Related]
17. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
18. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
19. NKX2-8 deletion-induced reprogramming of fatty acid metabolism confers chemoresistance in epithelial ovarian cancer.
Zhu J; Wu G; Song L; Cao L; Tan Z; Tang M; Li Z; Shi D; Zhang S; Li J
EBioMedicine; 2019 May; 43():238-252. PubMed ID: 31047858
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
